State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai 200001, China.
State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai 200001, China.
Cell. 2024 Jun 20;187(13):3231-3232. doi: 10.1016/j.cell.2024.04.044.
Numerous studies have evaluated the gut microbiome as a biomarker for predicting cancer immunotherapy, but the heterogeneity among different studies has hindered its applications. In this issue of Cell, Derosa et al. report a biomarker based on the ecological topology of the gut microbiota that can predict immunotherapy efficacy effectively.
许多研究已经评估了肠道微生物组作为预测癌症免疫治疗的生物标志物，但不同研究之间的异质性阻碍了其应用。在本期《细胞》杂志上，Derosa 等人报告了一种基于肠道微生物群生态拓扑结构的生物标志物，该标志物可以有效地预测免疫治疗的疗效。
